Madrigal Pharmaceuticals (MDGL) Other Operating Expenses (2016 - 2026)

Madrigal Pharmaceuticals (MDGL) has 4 years of Other Operating Expenses data on file, last reported at $26.8 million in Q1 2026.

• On a quarterly basis, Other Operating Expenses rose 494.88% year-over-year to $26.8 million in Q1 2026; TTM through Mar 2026 was $673.7 million, a 165.71% increase from a year earlier, with the FY2025 full-year figure at $56.1 million, up 108.44% from the prior year.
• Other Operating Expenses for Q1 2026 stood at $26.8 million, down from $870.6 million in the prior quarter.
• Over the last five years, Other Operating Expenses for MDGL reached as high as $870.6 million in Q4 2025 and fell as low as -$679.6 million in Q4 2024.
• Historically, Other Operating Expenses has averaged -$55.9 million across 3 years, with a median of -$152.0 million in 2024.
• Across the five-year window, Other Operating Expenses slumped 37.5% in 2025 and surged 494.88% in 2026, its largest moves.
• Year by year, Other Operating Expenses stood at -$679.6 million in 2024, then surged by 228.1% to $870.6 million in 2025, then slumped by 96.92% to $26.8 million in 2026.
• Per Business Quant data, the three most recent Other Operating Expenses figures were $26.8 million in Q1 2026, $870.6 million in Q4 2025, and $18.1 million in Q3 2025.